LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Stock List・MannKind Corp

MannKind Corp

Closed

SectorHealthcare

3.54 -1.12

Buy Sell

Overview

Share price change

24h

Current

Min

3.37

Max

3.86

Key metrics
By Trading Economics
Income	-24M -16M
Sales	30M 112M
P/E Sector Avg	140.5 49.8
EPS	0.01
Profit margin	-14.245
Employees	591
EBITDA	-20M -2.5M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+111.8% upside

Market Stats
By TradingEconomics
Market Cap	-689M 868M
Previous open	4.66
Previous close	3.54

News Sentiment

By Acuity

12%

88%

10 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

4.079 / 4.323 Support & Resistance

MannKind Corp Chart

Past performance is not a reliable indicator of future results.

Related News

6 May 2026, 23:41 UTC

Earnings

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 May 2026, 21:40 UTC

Earnings

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 May 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 May 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 May 2026, 23:13 UTC

Earnings

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 May 2026, 23:13 UTC

Earnings

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 May 2026, 23:12 UTC

Earnings

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 May 2026, 23:11 UTC

Earnings

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 May 2026, 23:07 UTC

Earnings

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 May 2026, 23:06 UTC

Earnings

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 May 2026, 23:06 UTC

Earnings

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 May 2026, 23:05 UTC

Earnings

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 May 2026, 23:04 UTC

Earnings

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 May 2026, 22:50 UTC

Earnings

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 May 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 May 2026, 22:11 UTC

Earnings

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 May 2026, 22:11 UTC

Earnings

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 May 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 May 2026, 21:58 UTC

Earnings

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 May 2026, 21:47 UTC

Market Talk

Earnings

Costco Posts 13% Sales Growth in April -- Market Talk

6 May 2026, 21:46 UTC

Earnings

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 May 2026, 21:40 UTC

Earnings

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 May 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 May 2026, 21:32 UTC

Hot Stocks

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 May 2026, 21:29 UTC

Earnings

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

111.8% upside

12 Months Forecast

Average 7.54 USD 111.8%

High 10 USD

Low 4.75 USD

Based on 8 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

10 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.